Intech Investment Management LLC Makes New Investment in OraSure Technologies, Inc. (NASDAQ:OSUR)

Intech Investment Management LLC bought a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,688 shares of the medical instruments supplier’s stock, valued at approximately $84,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. increased its holdings in OraSure Technologies by 78.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 12,604 shares during the period. Factorial Partners LLC increased its stake in shares of OraSure Technologies by 12.0% during the third quarter. Factorial Partners LLC now owns 339,953 shares of the medical instruments supplier’s stock valued at $1,452,000 after buying an additional 36,326 shares during the period. Empowered Funds LLC raised its holdings in shares of OraSure Technologies by 22.6% in the third quarter. Empowered Funds LLC now owns 359,419 shares of the medical instruments supplier’s stock valued at $1,535,000 after acquiring an additional 66,210 shares in the last quarter. Principal Financial Group Inc. lifted its stake in OraSure Technologies by 28.1% in the third quarter. Principal Financial Group Inc. now owns 66,060 shares of the medical instruments supplier’s stock worth $282,000 after acquiring an additional 14,480 shares during the period. Finally, Ballentine Partners LLC purchased a new stake in OraSure Technologies in the third quarter worth about $159,000. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Trading Up 1.8 %

Shares of NASDAQ:OSUR opened at $3.91 on Monday. The company has a market capitalization of $291.65 million, a PE ratio of 26.07 and a beta of 0.03. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The business’s fifty day simple moving average is $4.04 and its 200-day simple moving average is $4.25.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The firm’s quarterly revenue was down 55.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.27 earnings per share. Research analysts predict that OraSure Technologies, Inc. will post -0.07 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.